Comorbid functional pathology in gastroenterology. Possibilities and prospects for drug treatment: A review

Cover Page

Cite item

Full Text

Abstract

Functional disorders of the gastrointestinal tract (FD GT) and their intersection are relevant due to their high prevalence in the population, decrease and, in some cases, loss of performance, low quality of life and treatment difficulties. Despite the large number of consensuses and clinical recommendations at the national and international level, the effectiveness of therapy for FD GT and their overlap does not exceed 30-50%. There is a high degree of comorbidity of these diseases, called “overlap syndromes,” due to common pathogenetic mechanisms. This predetermines the need to use drugs with a multi-target therapeutic effect in the treatment of such pathology. Such drugs include trimebutine (Trimedate®), probiotics and psychotropic drugs. Data obtained in recent years on the presence of anti-inflammatory, antimicrobial, regenerative effects in relation to nervous and epithelial tissue and anti-carcinogenic effects in trimebutine make it unique for the treatment of gastrointestinal diseases and their intersection. Currently, there is a search for new promising drugs for the treatment of both individual FD GT and their overlap, as well as improving the regimens of existing treatment methods. The review article is devoted to existing opportunities and new horizons for the treatment of FD GT and their overlap.

About the authors

Alexey M. Osadchuk

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: a.m.osadchuk2020@mail.ru
ORCID iD: 0000-0002-8488-9235

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Irina D. Loranskaya

Russian Medical Academy of Continuous Professional Education

Email: gastromapo@yandex.ru
ORCID iD: 0000-0002-3681-4132

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Mikhail A. Osadchuk

Sechenov First Moscow State Medical University (Sechenov University)

Email: osadchuk.mikhail@yandex.ru
ORCID iD: 0000-0003-0485-6802

D. Sci. (Med.), Prof.

Russian Federation, Moscow

References

  1. Madisch A, Andresen V, Enck P, et al. The Diagnosis and Treatment of Functional Dyspepsia. Dtsch Arztebl Int. 2018;115(13):222-32. doi: 10.3238/arztebl.2018.0222
  2. Sperber AD, Freud T, Aziz I, et al. Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clin Gastroenterol Hepatol. 2022;20(5):e945-56. doi: 10.1016/j.cgh.2021.05.042
  3. Huang KY, Wang FY, Lv M, et al. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol. 2023;29(26):4120-35. doi: 10.3748/wjg.v29.i26.4120
  4. Stoieva TV, Platonova OM, Dzhagiashvili OV. Overlapping Influence the Psychoemotional Profile among Children with Functional Gastrointestinal Disorders. Int J Fam Med Prim Care. 2020;1(5):1025.
  5. Нижевич А.А., Гимазетдинова Р.Ш., Туйгунов М.М., Якупова Г.М. Билиарная дискинезия у детей с синдромом раздраженного кишечника: overlap-синдром. Поиски современного подхода к терапии абдоминального болевого синдрома. Российский вестник перинатологии и педиатрии. 2021;66(6):121-8 [Nizhevitch AA, Gimazetdinova RSh, Tuygunov MM, Yakupova GM. Biliary dyskinesia in children with irritable bowel syndrome: overlap syndrome. The search for a modern approach to the treatment of abdominal pain syndrome. Russian Bulletin of Perinatology and Pediatrics. 2021;66(6):121-8 (in Russian)]. doi: 10.21508/1027-4065-2021-66-6-121-128
  6. Ивашкин В.Т., Маев И.В., Шульпекова Ю.О., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению дискинезии желчевыводящих путей. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(3):63-80 [Ivashkin VT, Mayev IV, Shulpekova YuO, et al. Diagnostics and treatment of biliary dyskinesia: clinical guidelines of the Russian gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):63-80 (in Russian)]. doi: 10.22416/1382-4376-2018-28-3-63-80
  7. Лоранская И.Д., Вишневская В.В. Изучение моторной функции желчевыделительной системы и гастродуоденальной зоны при патологии билиарного тракта. Русский медицинский журнал. 2005;7(1):1-7 [Loranskaya ID, Vishnevskaya VV. Study of the motor function of the biliary system and gastroduodenal zone in pathology of the biliary tract. Russian Medical Journal. 2005;7(1):1-7 (in Russian)].
  8. Яковенко Э.П., Агафонова Н.А., Яковенко А.В., и др. Агонист опиатных рецепторов тримебутин в терапии функциональных расстройств желчного пузыря и сфинктера Одди. Лечащий врач. 2014;(2):56-60 [Yakovenko EP, Agafonova NA, Yakovenko AV, et al. Opiate receptor agonist trimebutine in the treatment of functional disorders of the gallbladder and sphincter of Oddi. Lechaschi Vrach. 2014;(2):56-60 (in Russian)].
  9. Zádori N, Németh D, Frim L, et al. Dyspepsia-Like Symptoms in Helicobacter pylori-Negative Chronic Gastritis are Associated with ASCA-, ANCA-, and Celiac Seropositivity but Not with Other Autoimmune Parameters: A Single-Centre, Retrospective Cross-Sectional Study. Int J Gen Med. 2022;15:7789-96. doi: 10.2147/IJGM.S380419
  10. Alamo RZ, Quigley EMM. Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches. Curr Opin Gastroenterol. 2019;35(1):27-33. doi: 10.1097/MOG.0000000000000499
  11. Calini G, Abd El Aziz MA, Paolini L, et al. Symptomatic Uncomplicated Diverticular Disease (SUDD): Practical Guidance and Challenges for Clinical Management. Clin Exp Gastroenterol. 2023;16:29-43. doi: 10.2147/CEG.S340929
  12. Usai-Satta P, Bassotti G, Bellini M, et al. Irritable Bowel Syndrome and Gluten-Related Disorders. Nutrients. 2020;12(4):1117. doi: 10.3390/nu12041117
  13. Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1053-62. doi: 10.1016/S2468-1253(20)30300-9
  14. Huang CT, Lee TH, Lin CK, et al. Pancreatic Fibrosis (Early Chronic Pancreatitis) as Emerging Diagnosis in Structural Causes of Dyspepsia: Evidence from Endoscopic Ultrasonography and Shear Wave Elastography. Diagnostics (Basel). 2021;11(7):1252. doi: 10.3390/diagnostics11071252
  15. Wang HH, Portincasa P, Liu M, et al. Similarities and differences between biliary sludge and microlithiasis: Their clinical and pathophysiological significances. Liver Res. 2018;2(4):186-99. doi: 10.1016/j.livres.2018.10.001
  16. Kозлова И.В., Быкова А.П., Осадчук М.А. Хронический панкреатит с СРК-подобным синдромом: подходы к терапии. Терапевтический архив. 2020;92(2):61-6 [Kozlova IV, Bykova AP, Osadchuk MA. Chronic pancreatitis with IBS-like syndrome: approach to therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):61-6 (in Russian)]. doi: 10.26442/00403660.2020.02.000518
  17. Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Шабуров Р.И. Современные достижения в лечении гастроэзофагеальной рефлюксной болезни: фокус на эзофагопротекцию. Терапевтический архив. 2019;91(8):4-11 [Maev IV, Andreev DN, Kucheryavyy YuA, Shaburov RI. Current advances in the treatment of gastroesophageal reflux disease: a focus on esophageal protection. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(8):4-11 (in Russian)].
  18. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95 [Ivashkin VT, Maev IV, Shelygin YuA, et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95 (in Russian)]. doi: 10.22416/1382-4376-2021-31-5-74-95
  19. Ford AC, Mahadeva S, Carbone MF, et al. Functional dyspepsia. Lancet. 2020;396(10263):1689-702. doi: 10.1016/S0140-6736(20)30469-4
  20. Lee I, Park SS. Diagnosis and treatment of reflux hypersensitivity with gastroesophageal reflux symptoms from a surgical perspective. Foregut Surg. 2022;2(Suppl. 1):8-16. doi: 10.51666/fs.2022.2.e1
  21. Roberts C, Albusoda A, Farmer AD, Aziz Q. Factors influencing rectal hypersensitivity in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil. 2023;35(4):e14515. doi: 10.1111/nmo.14515
  22. Осадчук А.М., Лоранская И.Д., Осадчук М.А. СРК-подобные синдромы в клинике внутренних болезней: современное состояние проблемы. Медицинский алфавит. 2021;1(6):36-40 [Osadchuk AM, Loranskaya ID, Osadchuk MA. IBS like syndromes in clinic of internal diseases: current state of problem. Medical alphabet. 2021;1(6):36-40 (in Russian)]. doi: 10.33667/2078-5631-2021-6-36-40
  23. Свистунов А.А., Осадчук М.А., Киреева Н.В., и др. Синдром раздраженного кишечника с сопутствующими заболеваниями желудка и пищевода (синдром перекреста): клинические и иммуноморфологические особенности. Медицинский вестник Северного Кавказа. 2018;13(2):325-9 [Svistunov AA, Osadchuk MA, Kireeva NV, et al. Irritable bowel syndrome with concomitant diseases of the stomach and esophagus (overlap syndrome): clinical and immunomorphological characteristics. Medical News of North Caucasus. 2018;13(2):325-9 (in Russian)]. doi: 10.14300/mnnc.2018.13041
  24. Мехтиев С.Н., Мехтиева О.А., Берко О.М. Синдром перекреста функциональных гастроинтестинальных расстройств: общие механизмы патогенеза как ключ к рациональной терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):95-103 [Mekhdiyev SN, Mekhdieva OA, Berko OM. Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):95-103 (in Russian)]. doi: 10.22416/1382-4376-2022-32-4-95-103
  25. Оганов Р.Г., Симаненков В.И., Бакулин И.Г., и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66 [Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66 (in Russian)]. doi: 10.15829/1728-8800-2019-1-5-66
  26. Лазебник Л.Б., Голованова Е.В., Волель Б.А., и др. Функциональные заболевания органов пищеварения. Синдромы перекреста. Клинические рекомендации Российского научного медицинского общества терапевтов и научного общества гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2021;(8):5-117 [Lazebnik LB, Golovanova EV, Volel BA, et al. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2021;(8):5-117 (in Russian)]. doi: 10.31146/1682-8658-ecg-192-8-5-117
  27. Осадчук М.А., Cвистунов А.А., Киреева Н.В., Осадчук М.М. Функциональные заболевания желудочно-кишечного тракта в контексте синдрома перекреста: современное состояние проблемы. Терапевтический архив. 2020;92(2):112-8 [Osadchuk MA, Svistunov AA, Kireeva NV, Osadchuk MM. Functional diseases of the gastrointestinal tract in the context with overlapping functional disorders: current status of the problem. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):112-8 (in Russian)]. doi: 10.26442/00403660.2020.02.000458
  28. Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue Barriers. 2017;5(4):e1373208. doi: 10.1080/21688370.2017.1373208
  29. Bousdouni P, Kandyliari A, Koutelidakis AE. Probiotics and Phytochemicals: Role on Gut Microbiota and Efficacy on Irritable Bowel Syndrome, Functional Dyspepsia, and Functional Constipation. Gastrointest Disord. 2022;4(1):30-48. doi: 10.3390/gidisord4010005
  30. Cheng J, Ouwehand AC. Gastroesophageal Reflux Disease and Probiotics: A Systematic Review. Nutrients. 2020;12(1):132. doi: 10.3390/nu12010132
  31. Yu L, Liu Y, Wang S, et al. Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies. Gut Microbes. 2023;15(1):2181930. doi: 10.1080/19490976.2023.2181930
  32. Wilson B, Rossi M, Dimidi E, Whelan K. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2019;109(4):1098-111. doi: 10.1093/ajcn/nqy376
  33. Salvioli B. Trimebutine: a state-of-the-art review. Minerva Gastroenterol Dietol. 2019;65(3):229-38.
  34. Свистунов А.А., Буторова Л.И., Осадчук М.А. Синдром билиарной боли в свете Римских критериев IV: рациональный подход к выбору спазмолитической терапии в клинической практике. Доказательная гастроэнтерология. 2018;7(2):59-69 [Svistunov AA, Butorova LI, Osadchuk MA, et al. The biliary pain syndrome in the context of the Rome IV diagnostic criteria: the rational approach to the choice of spasmolytic therapy in the clinical practice. Evidence-based gastroenterology. 2018;7(2):59-69 (in Russian)]. doi: 10.17116/dokgastro20187259
  35. Маев И.В., Самсонов А.А., Семенова А.В., и др. Опыт применения тримебутина малеата в режиме пролонгированной монотерапии у пациентов с синдромом раздраженного кишечника. Consilium Medicum. 2018;20(8):74-9 [Mayev IV, Samsonov AA, Semenova AV, et al. Experience in trimebutine maleate use in a prolonged monotherapy regimen in patients with irritable bowel syndrome. Consilium Medicum. 2018;20(8):74-9 (in Russian)]. doi: 10.26442/2075-1753_2018.8.74-79
  36. Ogawa N, Nakajima S, Tamada K, et al. Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages. Arch Biochem Biophys. 2021;711:109029. doi: 10.1016/j.abb.2021.109029
  37. Motawea A, Abd El Hady WE, Ahmed El-Emam G. The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis. Drug Deliv. 2022;29(1):906-24. doi: 10.1080/10717544.2022.2050847
  38. Xu J, Hu C, Jiang Q, et al. Trimebutine, a small molecule mimetic agonist of adhesion molecule L1, contributes to functional recovery after spinal cord injury in mice. Dis Model Mech. 2017;10(9):1117-28. doi: 10.1242/dmm.029801
  39. Ozkaya SN, Keskin T, Tekin C, et al. Investigation of the antitumor effects of anti-inflammatory desloratadine and trimebutine on different types of human cancer cells: An in vitro study. Annals of Medical Research. 2023;30(6):727-32.
  40. Lee H, Kwon OB, Lee JE, et al. Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells. Cells. 2021;10(4):918. doi: 10.3390/cells10040918
  41. Wu X, Wang J, Ye Z, et al. Risk of Colorectal Cancer in Patients With Irritable Bowel Syndrome: A Meta-Analysis of Population-Based Observational Studies. Front Med (Lausanne). 2022;9:819122. doi: 10.3389/fmed.2022.819122
  42. Hu LY, Ku FC, Lu T, et al. Risk of cancer in patients with irritable bowel syndrome: a nationwide population-based study. Ann Epidemiol. 2015;25(12):924-8. doi: 10.1016/j.annepidem.2015.07.006
  43. Kountouras J, Sofianou D, Gavalas E, et al. Trimebutine as a potential antimicrobial agent: a preliminary in vitro approach. Hippokratia. 2012;16(4):347-9.
  44. Boziki M, Grigoriadis N, Papaefthymiou A, et al. The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis. Neurochem Int. 2021;144:104938. doi: 10.1016/j.neuint.2020.104938
  45. Маев И.В., Андреев Д.Н. Эффективность тримебутина в рамках лечения функциональных заболеваний желудочно-кишечного тракта и желчных путей: наблюдательное многоцентровое исследование. Терапевтический архив. 2021;93(8):897-903 [Maev IV, Andreev DN. On behalf of the team of researchers of the TMD-06-02-2018 protocol. Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study. Terapevticheskii Arkhiv (Ter. Arkh). 2021;93(8):897-903 (in Russian)]. doi: 10.26442/00403660.2021.08.200919
  46. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-61. doi: 10.1046/j.1365-2036.2001.00937.x
  47. Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697-723. doi: 10.1136/gutjnl-2022-327737
  48. Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-40. doi: 10.1136/gutjnl-2021-324598
  49. Fowler S, Hoedt EC, Talley NJ, et al. Circadian Rhythms and Melatonin Metabolism in Patients With Disorders of Gut-Brain Interactions. Front Neurosci. 2022;16:825246. doi: 10.3389/fnins.2022.825246
  50. Свистунов А.А., Осадчук М.А., Осадчук А.М. Мелатонин и перспективы применения препаратов мелатонина в гастроэнтерологии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(5):6-12 [Svistunov AA, Osadchuk MA, Osadchuk AM. Melatonin and its therapeutic prospects in gastroenterology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):6-12 (in Russian)]. doi: 10.22416/1382-4376-2016-5-6-12
  51. Kim BT, Kim KM, Kim KN. The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial. Nutrients. 2020;12(5):1410. doi: 10.3390/nu12051410
  52. Colecchia A, Mazzella G, Sandri L, et al. Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World J Gastroenterol. 2006;12(33):5336-43. doi: 10.3748/wjg.v12.i33.5336

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies